Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 39-78 , July 2003

The economics of smoking and cardiovascular disease

  • James Lightwood

      Affiliations

    • Corresponding Author InformationReprint requests: James Lightwood, PhD, School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, 3333 California St, Suite 420, San Francisco, CA 94118, USA
    • School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA

References 

  1. National Center for Health Statistics . Health, United States, 2002 With Chartbook on Trends in the Health of Americans. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2002;
  2. Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. MMWR Morb Mortal Wkly Rep. 2002;51:300–303
  3. Gruber J. The economics of tobacco regulation. Only the costs that smokers impose on others justify a mandate for government action. Health Aff (Millwood). 2002;21:146–162
  4. Laux FL. Addiction as a market failure (Using rational addiction results to justify tobacco regulation). J Health Econ. 2000;19:421–437
  5. Collins DJ, Lapsley HM. Estimating the economic costs of drug abuse in Australia. National Campaign Against Drug Abuse (Australia). Monograph no. 15. Canberra: Australian Govt. Publishing Service; 1991; p 118
  6. Collins DJ, Lapsley HM. The social costs of drug abuse in Australia in 1988 and 1992. National Drug Strategy. Monograph no. 30. Canberra: Australian Govt. Publishing Service for the Commonwealth Department of Human Services and Health; 1996; p 74
  7. Warner KE, Fulton GA. The economic implications of tobacco product sales in a nontobacco state. JAMA. 1994;271:771–776
  8. Warner KE, Fulton GA, Nicolas P, et al.  Employment implications of declining tobacco product sales for the regional economies of the United States. JAMA. 1996;275:1241–1246
  9. Warner KE. The economics of tobacco (Myths and realities). Tob Control. 2000;9:78–89
  10. Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States (Estimates, their validity, and their implications). Tob Control. 1999;8:290–300
  11. Lightwood J, Collins D, Lapsley H, et al.  Estimating the cost of tobacco use. In:  Jha P,  Chaloupka FJ editor. Tobacco Control in Developing Countries. Oxford: Oxford University Press; 2000;p. 63–103
  12. Max W. The financial impact of smoking on health-related costs (A review of the literature). Am J Health Promot. 2001;15:321–331
  13. Hodgson TA, Cohen AJ. Medical care expenditures for selected circulatory diseases (Opportunities for reducing national health expenditures). Med Care. 1999;37:994–1012
  14. Druss BG, Marcus SC, Olfson M, et al.  The most expensive medical conditions in America. Health Aff (Millwood). 2002;21:105–111
  15. Druss BG, Marcus SC, Olfson M, et al.  Comparing the national economic burden of five chronic conditions. Health Aff (Millwood). 2001;20:233–241
  16. Ray GT, Collin F, Lieu T, et al.  The cost of health conditions in a health maintenance organization. Med Care Res Rev. 2000;57:92–109
  17. Dobkin B. The economic impact of stroke. Neurology. 1995;45(suppl 1):S6–S9
  18. Taylor TN. The medical economics of stroke. Drugs. 1997;54(suppl 3):51–58
  19. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause-2020 (Global Burden of Disease Study). Lancet. 1990;349:1498–1504
  20. Vorster HH. The emergence of cardiovascular disease during urbanisation of Africans. Public Health Nutr. 2002;5:239–243
  21. Weinstein MC, Coxson PC, Williams LW, et al.  Forecasting coronary heart disease incidence, mortality, and cost (The Coronary Heart Disease Policy Model). Am J Public Health. 1987;77:1417–1426
  22. Goldman L, Weinstein MC, Williams LW. Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Projections of the Coronary Heart Disease Policy Model. Circulation. 1989;80:254–260
  23. Edelson JT, Weinstein MC, et al.  Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990;263:407–413
  24. Tsevat J, Weinstein MC, Williams LW, et al.  Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation. 1991;83:1194–1201
  25. Tosteson AN, Weinstein MC, Williams LW, et al.  Long-term impact of smoking cessation on the incidence of coronary heart disease. Am J Public Health. 1990;80:1481–1486
  26. Goldman L, Phillips KA, Coxson P, et al.  The effect of risk factor reductions between 1981 and 1990 on coronary heart disease incidence, prevalence, mortality and cost. J Am Coll Cardiol. 2001;38:1012–1017
  27. United States Office on Smoking and Health and United States, Surgeon-General’s Office . The Health Consequences of Smoking: Cardiovascular Disease (A Report of the Surgeon General, 1983). Rockville, MD. Washington, DC: U.S. Department of Health and Human Services Public Health Service Office on Smoking and Health; 1983; pp xvii, 384
  28. Kleinbaum DG, Morgenstern H, Kupper LL. Epidemiologic research (Principles and quantitative methods). New York: Van Nostrand Reinhold; 1982; pp xix, 529
  29. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998; pp xiii, 737
  30. Eide GE, Gefeller O. Sequential and average attributable fractions as aids in the selection of preventive strategies. J Clin Epidemiol. 1995;48:645–655
  31. Luce BR, Schweitzer SO. Smoking and alcohol abuse (A comparison of their economic consequences). N Engl J Med. 1978;298:569–571
  32. Office of Technology Assessment, Smoking Related Deaths and Financial Costs . OTA Staff Memorandum. Washington DC: Health Program, U.S. Congress; 1985;
  33. Rice DP, Hodgson TA, Sinsheimer P, et al.  The economic costs of the health effects of smoking, 1984. Milbank Q. 1986;64:489–547
  34. Centers for Disease Control and Prevention, Smoking-Attributable Mortality, Morbidity, and Economic Costs (SAMMEC): Adult SAMMEC and Maternal and Child Health (MCH) SAMMEC software, 2002. Accessed: March 21 2003. Available: http://www.cdc.gov/tobacco/sammec
  35. Miller VP, Ernst C, Collin F. Smoking-attributable medical care costs in the USA. Soc Sci Med. 1999;48:375–391
  36. Thomas AR, Hedberg K, Fleming DW. Comparison of physician based reporting of tobacco attributable deaths and computer derived estimates of smoking attributable deaths, Oregon, to 1996. Tob Control. 1989;10:161–164
  37. Jin SG, Lu BY, Yan DY, et al.  An evaluation on smoking-induced health costs in China (1988–1989). Biomed Environ Sci. 1995;8:342–349
  38. Ruff LK, Volmer T, Nowak D, et al.  The economic impact of smoking in Germany. Eur Respir J. 2000;16:385–390
  39. Farley TM, Meirik O, Chang CL, et al.  Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998;52:775–785
  40. Puchmayer V. Smoking as a risk factor for the development of arterial occlusive disease. Acta Univ Carol Med Monogr. 1984;105:1–134
  41. Gorelick PB, Erkinjuntti T, Hofman A, et al.  Prevention of vascular dementia. Alzheimer Dis Assoc Disord. 1999;13(suppl 3):S131–S139
  42. Gillings DB. Pentoxifylline and intermittent claudication (Review of clinical trials and cost-effectiveness analyses). J Cardiovasc Pharmacol. 1995;25(suppl 2):S44–S50
  43. Lederle F, Johnson GR, Wilson SE, et al.  Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann Intern Med. 1997;126:441–449
  44. U.K. Small Aneurysm Trial Participants Brown L, Powell J. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. Ann Surg. 1999;230:289–297
  45. Chang M, Hahn RA, Teusch SM, et al.  Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971–1992. J Clin Epidemiol. 2001;54:634–644
  46. Gillum RF, Mussolino ME, Madans JH. Coronary heart disease risk factors and attributable risks in African-American women and men (NHANES I epidemiologic follow-up study). Am J Public Health. 1998;88:913–917
  47. Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med. 1999;28:343–348
  48. Nakayama T, Date C, Yokoyama T, et al.  Population attributable fraction of stroke incidence in middle-aged and elderly people (Contributions of hypertension, smoking and atrial fibrillation). Neuroepidemiology. 2000;19:217–226
  49. Malarcher AM, Schulman J, Epstein LA, et al.  Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol. 2000;152:573–584
  50. Sturmans F, Mulder PG, Valkenburg HA. Estimation of the possible effect of interventive measures in the area of ischemic heart diseases by the attributable risk percentage. Am J Epidemiol. 1977;105:281–289
  51. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths (Confounding in the courtroom). JAMA. 2000;284:706–712
  52. English D, Holman CDJ, Milne E, et al.  The Quantification of Drug Caused Morbidity and Mortality in Australia, 1995. Canberra: Commonwealth Department of Human Services and Health; 1995;
  53. Diverse Populations Collaborative Group . Prediction of mortality from coronary heart disease among diverse populations (Is there a common predictive function?). Heart. 2002;88:222–228
  54. Chambless LE, Dobson AJ, Patterson CC, et al.  On the use of a logistic risk score in predicting risk of coronary heart disease. Stat Med. 1990;9:385–396
  55. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Am Heart J. 1992;152:56–64
  56. Willett WC, Green A, Stampfer MJ, et al.  Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med. 1987;317:1303–1309
  57. Leffondre K, Abrahammowicz M, Siemźatycki J, et al.  Modeling smoking history (A comparison of different approaches). Am J Epidemiol. 2002;156:813–823
  58. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation (Myocardial infarction and stroke). Circulation. 1997;96:1089–1096
  59. United States Public Health Service, Office of the Surgeon General and Center for Chronic Disease Prevention and Health Promotion (U.S.), Office on Smoking and Health . The Health Benefits of Smoking Cessation (A Report of the Surgeon General, Rockville, MD). Washington, DC: U.S. Department of Health and Human Services Public Health Service Centers for Disease Control Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health; 1990; pp xxxiii, 628
  60. Ebbert JO, Yang P, Vachon CM, et al.  Lung cancer risk reduction after smoking cessation (Observations from a prospective cohort of women). J Clin Oncol. 2003;21:921–926
  61. Pohlabeln H, Jockel KH, Muller KM. The relation between various histological types of lung cancer and the number of years since cessation of smoking. Lung Cancer. 1997;18:223–229
  62. Eide GE, Heuch I. Attributable fractions (Fundamental concepts and their visualization). Stat Methods Med Res. 2001;10:159–193
  63. Benichou J. A review of adjusted estimators of attributable risk. Stat Methods Med Res. 2001;10:195–216
  64. Land M, Vogel C, Gefeller O. Partitioning methods for multifactorial risk attribution. Stat Methods Med Res. 2001;10:217–230
  65. Repace JL. The problem of passive smoking. Bull N Y Acad Med. 1981;57:936–946
  66. United States Office on Smoking and Health and United States Office of the Assistant Secretary for Health and Surgeon General . The Health Consequences of Involuntary Smoking (A Report of the Surgeon General, 1986, Rockville, MD). Washington, DC: U.S. Department of Health and Human Services Public Health Service Centers for Disease Control Center for Health Promotion and Education Office on Smoking and Health; 1986;
  67. Kawachi I, Pearce NE, Jackson RT. Deaths from lung cancer and ischaemic heart disease due to passive smoking in New Zealand. N Z Med J. 1989;102:337–340
  68. Dobson AJ, Alexander HM, Heller RF, et al.  Passive smoking and the risk of heart attack or coronary death. Med J Aust. 1991;154:793–797
  69. Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation. 1991;83:1–12
  70. California Environmental Protection Agency . Office of Environmental Health Hazard Assessment and National Cancer Institute (U.S.), Health Effects of Exposure to Environmental Tobacco Smoke (The report of the California Environmental Protection Agency). Bethesda, MD: U.S. Dept. of Health and Human Services Public Health Service National Institutes of Health National Cancer Institute; 1999; NIH publication no. 99-4645 pp xviii, 15, 430
  71. Department of Health UK . Report of the Scientific Committee on Tobacco and Health. London: The Stationary Office; 1998;
  72. National Health and Medical Research Council . The Health Effects of Passive Smoking (A Scientific Information Paper). Canberra, Australia: National Health and Medical Research Council of Australia; 1997;
  73. Committee on Passive Smoking, Board on Environmental Studies and Toxicology, and National Research Council, Environmental Tobacco Smoke . Measuring Exposures and Assessing Health Effects. Washington, DC: National Academy Press; 1986;
  74. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease (An evaluation of the evidence). BMJ. 1997;315:973–980
  75. Howard G, Thun MJ. Why is environmental tobacco smoke more strongly associated with coronary heart disease than expected? A review of potential biases and experimental data. Environ Health Perspect. 1999;107(suppl 6):853–858
  76. Kawachi I, Colditz GA. Invited commentary (Confounding, measurement error, and publication bias in studies of passive smoking). Am J Epidemiol. 1996;144:909–915
  77. Smith CJ, Fischer TH, Sears SB. Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis. Toxicol Sci. 2000;54:462–472
  78. Moskowitz WB, Schwartz PF, Schieken RM. Childhood passive smoking, race, and coronary artery disease risk (The MCV Twin Study. Medical College of Virginia). Arch Pediatr Adolesc Med. 1999;153:446–453
  79. Kawachi I, Colditz GA, Speizer FE, et al.  A prospective study of passive smoking and coronary heart disease. Circulation. 1997;95:2374–2379
  80. Kawachi I, Colditz GA. Workplace exposure to passive smoking and risk of cardiovascular disease (Summary of epidemiologic studies). Environ Health Perspect. 1999;107(suppl 6):847–851
  81. Burghuber OC, Puzengruber C, Sinzinger H, et al.  Platelet sensitivity to prostacyclin in smokers and non-smokers. Chest. 1986;90:34–38
  82. Otsuka R, Watanabe H, Hirata K, et al.  Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA. 2001;286:436–441
  83. He Y, Lam TH, Li LS, et al.  Passive smoking at work as a risk factor for coronary heart disease in Chinese women who have never smoked. BMJ. 1994;308:380–384
  84. Sarget R, Shepard R, Glantz S. Immediate reduction in acute myocardial infarction after the implementation of a comprehensive smokefree ordinance. In: Annual Scientific Sessions of the American College of Cardiology, March 30–April 2, 2003 Chicago, IL. 2003;
  85. Kupersmith J, Holmes-Rouner M, Hogan A, et al.  Cost-effectiveness analysis in heart disease, Part I (General principles). Prog Cardiovasc Dis. 1994;37:161–184
  86. Gold MR. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996; pp xxiii, 425
  87. Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J Publ Econ. 1973;2:147–157
  88. Johansson P. Evaluating health risks (An economic approach). New York: Cambridge University Press; 1995; p 190
  89. Laska EM, Meisner M, Siegal C, et al.  Ratio-based and net benefit-based approaches to health care resource allocation (Proofs of optimality and equivalence). Health Econ. 1999;8:171–174
  90. Kupersmith J, Holmes-Rouner M, Hogan A, et al.  Cost-effectiveness analysis in heart disease, Part II (Preventive therapies). Prog Cardiovasc Dis. 1995;37:243–271
  91. Kupersmith J, Holmes-Rouner M, Hogan A, et al.  Cost-effectiveness analysis in heart disease, Part III (Ischemia, congestive heart failure, and arrhythmias). Prog Cardiovasc Dis. 1995;37:307–346
  92. Tengs TO, Adams ME, Pliskin JS, et al.  Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis. 1995;15:369–390
  93. Zerbe R, Dively D. Benefit-cost analysis in theory and practice. New York: HarperCollins College Publishers; 1994; p 557
  94. Ritvo PG, Irvine MJ, Lindsay EA, et al.  A critical review of research related to family physician-assisted smoking cessation interventions. Cancer Prev Control. 1997;1:289–303
  95. Burns DM. Reducing tobacco use (What works in the population?). J Dent Educ. 2002;66:1051–1060
  96. Brownson RC, Eriksen MP, Davis RM, et al.  Environmental tobacco smoke (Health effects and policies to reduce exposure). Annu Rev Public Health. 1997;18:163–185
  97. Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour (Systematic review). BMJ. 2002;325:188
  98. Moskowitz JM, Lin Z, Hudes ES. The impact of workplace smoking ordinances in California on smoking cessation. Am J Public Health. 2000;90:757–761
  99. Longo DR, Johnson JC, Kruse RL, et al.  A prospective investigation of the impact of smoking bans on tobacco cessation and relapse. Tob Control. 2001;10:267–272
  100. Office of Air and Radiation . Indoor Air Division, The Costs and Benefits of Smoking Restrictions (An Assessment of the Smoke-Free Environment Act of 1993). Washington, DC: United States Environmental Protection Agency; 1994;
  101. Parrott S, Godfrey C, Raw M. Costs of employee smoking in the workplace in Scotland. Tob Control. 2000;9:187–192
  102. Bartosch WJ, Pope GC. Economic effect of restaurant smoking restrictions on restaurant business in Massachusetts, 1992 to 1998. Tob Control. 2001;11(suppl 2):ii38–ii42
  103. Cremieux PY, Ouellette P. Actual and perceived impacts of tobacco regulation on restaurants and firms. Tob Control. 2001;10:33–37
  104. Glantz SA, Smith LR. The effect of ordinances requiring smoke-free restaurants and bars on revenues (A follow-up). Am J Public Health. 1997;87:1687–1693
  105. Glantz SA, Charlesworth A. Tourism and hotel revenues before and after passage of smoke-free restaurant ordinances. JAMA. 1999;281:1911–1918
  106. Wakefield M, Siahpush M, Scollo M, et al.  The effect of a smoke-free law on restaurant business in South Australia. Aust N Z J Public Health. 2002;26:375–382
  107. Brownson RC, Hopkins DP, Wakefield MA. Effects of smoking restrictions in the workplace. Annu Rev Public Health. 2002;23:333–348
  108. Siegel M. The effectiveness of state-level tobacco control interventions (A review of program implementation and behavioral outcomes). Annu Rev Public Health. 2002;23:45–71
  109. Siegel M, Mowry PD, Pechecek TP, et al.  Trends in adult cigarette smoking in California compared with the rest of the United States, 1978–1994. Am J Public Health. 2000;90:372–379
  110. Pierce JP, Gilpin EA, Emery SL, et al.  Has the California tobacco control program reduced smoking?. JAMA. 1998;280:893–899
  111. Fichtenberg CM, Glantz SA. Association of the California Tobacco Control Program with declines in cigarette consumption and mortality from heart disease. N Engl J Med. 2000;343:1772–1777
  112. Gilpin EA, Pierce JP. The California Tobacco Control Program and potential harm reduction through reduced cigarette consumption in continuing smokers. Nicotine Tob Res. 2002;4(suppl 2):S157–S166
  113. Decline in cigarette consumption following implementation of a comprehensive tobacco prevention and education program—Oregon, 1996–1998. MMWR Morb Mortal Wkly Rep. 1999;48:140–143
  114. Biener L, Harris JE, Hamilton W. Impact of the Massachusetts tobacco control programme (Population based trend analysis). BMJ. 2000;321:351–354
  115. Manley MW, Pierce JP, Gilpin EA, et al.  Impact of the American Stop Smoking Intervention Study on cigarette consumption. Tob Control. 1997;6(suppl 2):S12–S16
  116. Luke DA, Stamatakis KA, Brownson RC. State youth-access tobacco control policies and youth smoking behavior in the United States. Am J Prev Med. 2000;19:180–187
  117. DiFranza JR, Peck RM, Radechi TE, et al.  What is the potential cost-effectiveness of enforcing a prohibition on the sale of tobacco to minors?. Prev Med. 2001;32:168–174
  118. Costs of smoking among active duty U.S. Air Force personnel—United States, 1997. MMWR Morb Mortal Wkly Rep. 2000;49:441–445
  119. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol. 1998;148:249–258
  120. Pierce JP, Gilpin E. How long will today’s new adolescent smoker be addicted to cigarettes?. Am J Public Health. 1996;86:253–256
  121. D’Onofrio CN, Moskowitz JM, Braverman MT. Curtailing tobacco use among youth (Evaluation of project 4-health). Health Educ Behav. 2002;29:656–682
  122. Livingood WC, Woodhouse CD, Sayre JJ, et al.  Impact study of tobacco possession law enforcement in Florida. Health Educ Behav. 2001;28:733–748
  123. Stead LF, Lancaster T. Interventions for preventing tobacco sales to minors. Cochrane Database Syst Rev. 2002;1:CD 001497
  124. Siegel M, Biener L, Rigotti NA. The effect of local tobacco sales laws on adolescent smoking initiation. Prev Med. 1999;29:334–342
  125. Sowden A, Arblaster L, Stead L. Community interventions for preventing smoking in young people. Cochrane Database Syst Rev. 2003;(1):CD 001291
  126. Friend K, Levy DT. Reductions in smoking prevalence and cigarette consumption associated with mass-media campaigns. Health Educ Res. 2002;17:85–98
  127. Fichtenberg CM, Glantz SA. Youth access interventions do not affect youth smoking. Pediatrics. 2002;109:1088–1092
  128. Difranza JR. Youth access (The baby and the bath water). Tob Control. 2000;9:120–121
  129. DiFranza JR. Is it time to abandon youth access programmes?. Tob Control. 2002;11:282–284
  130. Lantz PM, Jacobson PD, Warner KE, et al.  Investing in youth tobacco control (A review of smoking prevention and control strategies). Tob Control. 2000;9:47–63
  131. Elixhauser A. The costs of smoking and the cost effectiveness of smoking-cessation programs. J Public Health Policy. 1990;11:218–237
  132. Warnecke RB, Langenberg P, Wong SC, et al.  The second Chicago televised smoking cessation program (A 24-month follow-up). Am J Public Health. 1992;82:835–840
  133. Secker-Walker R, Ginch W, Platt S, et al.  Community interventions for reducing smoking among adults Cochrane. Database Syst Rev. 2002;(4):CD 001293
  134. Paul CL, Sanson-Fisher RW. Experts’ agreement on the relative effectiveness of 29 smoking reduction strategies. Prev Med. 1996;25:517–526
  135. Sellers DE, Crawford SL, Bullock K, et al.  Understanding the variability in the effectiveness of community heart health programs (A meta-analysis). Soc Sci Med. 1997;44:1325–1339
  136. Ebrahim S, Smith GD. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ. 1997;314:1666–1674
  137. Farrelly MC, Healton CG, Davis KC, et al.  Getting to the truth (Evaluating national tobacco countermarketing campaigns). Am J Public Health. 2002;92:901–907
  138. Goldman LK, Glantz SA. Evaluation of antismoking advertising campaigns. JAMA. 1998;279:772–777
  139. Pechmann C, Reibling ET. Anti-smoking advertising campaigns targeting youth (Case studies from USA and Canada). Tob Control. 2000;9(suppl 2):II18–II31
  140. Sly DF, Trapido E, Ray S. Evidence of the dose effects of an antitobacco counteradvertising campaign. Prev Med. 2002;35:511–518
  141. Secker-Walker RH, Worden JK, Holland RR, et al.  A mass media programme to prevent smoking among adolescents (Costs and cost effectiveness). Tob Control. 1997;6:207–212
  142. Ratcliffe J, Cairns J, Platt S. Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. Tob Control. 1997;6:104–110
  143. Stevens W, Thorogood M, Kayikki S. Cost-effectiveness of a community anti-smoking campaign targeted at a high risk group in London. Health Promot Int. 2002;17:43–50
  144. Thomas R. School based programmes for preventing smoking. (Cochrane Review) Cochrane Library. 2003;1:
  145. Wang LY, Crossett LS, Lowry R, et al.  Cost-effectiveness of a school-based tobacco-use prevention program. Arch Pediatr Adolesc Med. 2001;155:1043–1050
  146. Ketola E, Sipila R, Makela M. Effectiveness of individual lifestyle interventions in reducing cardiovascular disease and risk factors. Ann Med. 2000;32:239–251
  147. Salkeld G, Phongsavan P, Oldenburg B, et al.  The cost-effectiveness of a cardiovascular risk reduction program in general practice. Health Policy. 1997;41:105–119
  148. Emmons KM, Linnan LA, Shadel WG, et al.  The Working Healthy Project (A worksite health-promotion trial targeting physical activity, diet, and smoking). J Occup Environ Med. 1999;41:545–555
  149. Warner KE, Smith RJ, Smith DG, et al.  Health and economic implications of a work-site smoking-cessation program (A simulation analysis). J Occup Environ Med. 1996;38:981–992
  150. Ringen K, Anderson N, McAfee T, et al.  Smoking cessation in a blue-collar population (Results from an evidence-based pilot program). Am J Ind Med. 2002;42:367–377
  151. Fiore M, Bailey WC, Cohen SJ, et al.  Treating Tobacco Use and Dependence Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Services; 2000;
  152. Erfurt JC, Foote A, Heirich MA. Worksite wellness programs (Incremental comparison of screening and referral alone, health education, follow-up counseling, and plant organization). Am J Health Promot. 1991;5:438–448
  153. Eriksen MP, Gottlieb NH. A review of the health impact of smoking control at the workplace. Am J Health Promot. 1998;13:83–104
  154. Cohen DR, Fowler GH. Economic implications of smoking cessation therapies (A review of economic appraisals). Pharmacoeconomics. 1993;4:331–344
  155. Mudde AN, de Vries H, Strecher VJ. Cost-effectiveness of smoking cessation modalities (Comparing apples with oranges?). Prev Med. 1996;25:708–716
  156. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics. 1997;11:538–549
  157. Friend K, Levy DT. Smoking treatment interventions and policies to promote their use (A critical review). Nicotine Tob Res. 2001;3:299–310
  158. Brown AD, Garber AM. Cost effectiveness of coronary heart disease prevention strategies in adults. Pharmacoeconomics. 1998;14:27–48
  159. Silagy C, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2001;(2):CD 0001165
  160. Lancaster T, Stead L. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2002;(3):CD001292
  161. Stead L, Lancaster T, Perera R. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2003;(1):CD 002850
  162. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2002;(3):CD 001007
  163. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2002;(1):CD 000031
  164. Silagy C, Lancaster T, Stead L, et al.  Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002;(4):CD 000146
  165. Woolacott NF, Jones L, Forbes CA, et al.  The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation (A systematic review and economic evaluation). Health Technol Assess. 2002;6:1–245
  166. Keeler TE, Hu TW, Keith A, et al.  The benefits of switching smoking cessation drugs to over-the-counter status. Health Econ. 2002;11:389–402
  167. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA. 2002;288:1260–1264
  168. Franzon M, Gustavsson G, Korberly BH. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation (Discussion). JAMA. 2002;288:3208–3210
  169. Kristein MM. How much can business expect to profit from smoking cessation?. Prev Med. 1983;12:358–381
  170. Oster G, Huse DM, Delea TE, et al.  Cost-effectiveness of nicotine gum as an adjunct to physician’s advice against cigarette smoking. JAMA. 1986;256:1315–1318
  171. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA. 1989;261:75–79
  172. Cromwell J, Bartosch WJ, Fiore MC, et al.  Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation (Agency for Health Care Policy and Research). JAMA. 1997;278:1759–1766
  173. Wasley MA, McNagny SE, Phillips VL, et al.  The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Prev Med. 1997;26:264–270
  174. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling. JAMA. 1996;275:1247–1251
  175. Song F, Raftery J, Aveyard P, et al.  Cost-effectiveness of pharmacological interventions for smoking cessation (A literature review and a decision analytic analysis). Med Decis Making. 2002;22(Suppl):S26–S37
  176. Croghan IT, Offord KP, Evans RW, et al.  Cost-effectiveness of treating nicotine dependence (The Mayo Clinic experience). Mayo Clin Proc. 1997;72:917–924
  177. Tran MT, Holford DA, Kennedy DT, et al.  Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy. 2002;22:1623–1631
  178. Kennedy DT, Small RE. Development and implementation of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc (Wash). 2002;42:83–92
  179. Kennedy DT, et al.  Results of a smoking cessation clinic in community pharmacy practice. J Am Pharm Assoc (Wash). 2002;42:51–56
  180. Wilhelmsson C, Vedin A, Wilhelmsen L. Cost-benefit aspects of post-myocardial infarction intervention. Acta Med Scand Suppl. 1981;651:317–321
  181. Wilson K, Gibson N, William A, et al.  Effect of smoking cessation on mortality after myocardial infarction (Meta-analysis of cohort studies). Arch Intern Med. 2000;160:939–944
  182. Krumholz HM, Cohen BJ, Tsevat J, et al.  Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol. 1993;22:1697–1702
  183. Goldstein MG, Niaura R. Methods to enhance smoking cessation after myocardial infarction. Med Clin North Am. 2000;84:63–80 viii
  184. Shinton R. Lifelong exposures and the potential for stroke prevention (The contribution of cigarette smoking, exercise, and body fat). J Epidemiol Community Health. 1997;51:138–143
  185. Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention (Scientific review). JAMA. 2002;288:1388–1395
  186. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke (Evidence, costs, and effects on individuals and populations). Lancet. 1999;354:1457–1463
  187. Suskin N, Sheth T, Negassa A, et al.  Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol. 2001;37:1677–1682
  188. Lightwood J, Fleischmann KE, Glantz SA. Smoking cessation in heart failure (It is never too late). J Am Coll Cardiol. 2001;37:1683–1684
  189. Rigotti NA, Munafo MR, Murphy MF, et al.  Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2003;(1):CD 001837
  190. Meenan RT, Stevens VJ, Hornbrook MC, et al.  Cost-effectiveness of a hospital-based smoking cessation intervention. Med Care. 1998;36:670–678
  191. Moller A, Villebro N, Pedersen T. Interventions for preoperative smoking cessation. Cochrane Database Syst Rev. 2001;(4):CD 002294
  192. Fiore M. United States. Smoking Cessation Guideline Panel, and Centers for Disease Control and Prevention (U.S.), smoking cessation. Rockville, MD: U.S. Dept. of Health and Human Services Public Health Service Agency for Health Care Policy and Research Centers for Disease Control and Prevention; 1996; Clinical practice guideline no. 18. AHCPR publication no. 96-0692 pp viii, 125
  193. Buck DJ, Richmond RL, Mendelsohn CP. Cost-effectiveness analysis of a family physician delivered smoking cessation program. Prev Med. 2000;31:641–648
  194. Curry SJ, Grothaus LC, McAfee T, et al.  Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. N Engl J Med. 1998;339:673–679
  195. Halpern MT, Khan ZM, Young TL, et al.  Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm. 2000;57:1421–1429
  196. McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking-cessation interventions. Am J Health Syst Pharm. 1996;53:45–52
  197. Nielsen K, Fiore MC. Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation. Prev Med. 2000;30:209–216
  198. Zhu S, Melcer T, Sun J, et al.  Smoking cessation with and without assistance (A population-based analysis). Am J Prev Med. 2000;18:305–311
  199. Schauffler HH, McMenamin S, Olson K, et al.  Variations in treatment benefits influence smoking cessation (Results of a randomised controlled trial). Tob Control. 2001;10:175–180
  200. Manley MW, Griffen T, Foldes SS, et al.  The role of health plans in tobacco control. Annu Rev Public Health. 2003;24:247–266
  201. Next Generation California Tobacco Control Alliance: Available: http://www.tobaccofreealliance.org/. Accessed 2003
  202. State Tobacco Education and Prevention Partnership (STEPP): Available: http://www.cdphe.state.co.us/pp/tobacco/tobaccohom.asp. Accessed: 2003
  203. Hodgson TA. Cigarette smoking and lifetime medical expenditures. Milbank Q. 1992;70:81–125
  204. Daviglus ML, Liu K, Greenland P, et al.  Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs. N Engl J Med. 1998;339:1122–1129
  205. Schauffler HH, D’Agostino RB, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs (The Framingham Study). Am J Prev Med. 1993;9:146–154
  206. Levy DT, Chaloupka F, Gitchell J, et al.  The use of simulation models for the surveillance, justification and understanding of tobacco control policies. Health Care Manag Sci. 2002;5:113–120
  207. McAnulty J, Hopkins DD, Grant-Worley JA, et al.  A comparison of alternative systems for measuring smoking-attributable deaths in Oregon, USA. Tob Control. 1994;3:115–119
  208. Pronk NP, Goodman MJ, O’Connor PJ, et al.  Relationship between modifiable health risks and short-term health care charges. JAMA. 1999;282:2235–2239
  209. Edington DW, Yen LT, Witting P. The financial impact of changes in personal health practices. J Occup Environ Med. 1997;39:1037–1046
  210. Feingold E. Health care reform—more than cost containment and universal access. Am J Public Health. 1994;84:727–728
  211. Yen LT, Edington DW, Witting P. Associations between health risk appraisal scores and employee medical claims costs in a manufacturing company. Am J Health Promot. 1991;6:46–64
  212. Pelletier KR. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the worksite (1991–1993 update). Am J Health Promot. 1991;8:50–62
  213. Haynes G, Dunnagan T. Comparing changes in health risk factors and medical costs over time. Am J Health Promot. 2002;17:112–121
  214. Fichtenberg C, Glantz S. Controlling tobacco use (Discussion and reply). N Engl J Med. 2001;344:1797–1798
  215. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1975;81:380–386
  216. Hunink MG, Goldman L, Tosteson AN, et al.  The recent decline in mortality from coronary heart disease, 1980–1990 (The effect of secular trends in risk factors and treatment). JAMA. 1997;277:535–542
  217. Moore M, Hughes J. The health care consequences of smoking. Washington, DC: National Bureau of Economic Research; 2000;

☆ Supported by the Flight Attendant Medical Research Institute and the California Tobacco-Related Disease Research Program (California TRDRP) grant 8RT-0007.

PII: S0033-0620(03)00077-X

doi: 10.1016/S0033-0620(03)00077-X

Progress in Cardiovascular Diseases
Volume 46, Issue 1 , Pages 39-78 , July 2003

Article Tools